top of page

Ongoing Clinical Trials in
Lupus Nephritis

Ravulizumab – SANCTUARY


Ravulizumab is a long-acting terminal complement inhibitor that specifically binds to the complement protein C5 in the terminal complement...

Belimumab - BEAM


Belimumab is a monoclonal antibody against B-cell activating factor (BAFF), and by blocking the B-cell activating factor, it interferes with B-cell...

KYV-101 - CD19-directed CAR-T cell therapy


A chimeric antigen receptor (CAR) is a cellular receptor engineered to connect an extracellular targeting function with intracellular domains that activate...

Umbilical cord mesenchymal stem cells(MSCs) vs IL-2


An acquired deficiency of the cytokine interleukin-2 (IL-2) and associated disturbances in regulatory T cell (Treg) homeostasis play a crucial role...

CABA-201


A chimeric antigen receptor (CAR) is a cellular receptor engineered to connect an extracellular targeting function with intracellular domains...

Mesenchymal Stem cells (MSE_LE)


Mesenchymal stem cells (MSCs) are derived from bone marrow and are capable of differentiating into a variety of mesenchymal lineages and also possess...

LNP023 (Iptacopan)


LNP023 is a small-molecule, oral, and selective inhibitor of factor B, a key component of the complement alternative pathway...

Efgartigimod


Efgartigimod is a humanized IgG1 Fc fragment that binds to the neonatal Fc receptor and inhibits its interaction with IgG, thereby reducing IgG...

ANIFROLUMAB - IRIS STUDY


Anifrolumab is a human monoclonal antibody to the type I interferon (IFN) receptor subunit 1, which blocks the action of type I IFNs...

Telitacicept


Telitacicept (RC-18) is a novel, recombinant fusion protein, consisting of transmembrane activator and calcium modulator and...

Minimizing Glucocorticoid administration in patients with Proliferative Lupus Nephritis (GLUREDLUP)


The aim of the study is to evaluate the efficacy of a therapeutic regimen which decreases glucocorticoid exposure compared with standard therapy...

Baricitinib


Baricitinib is an oral selective inhibitor of Janus kinase 1 and 2. Previous studies have shown that baricitinib significantly reduced the concentration...

Obinutuzumab - OBILUP


Obinutuzumab is a humanized, type II anti-CD20 monoclonal antibody that has a distinct mode of binding to the CD20 antigen compared with type I...

CD19/BCMA Chimeric Antigen Receptor T Cells Therapy


A chimeric antigen receptor (CAR) is a cellular receptor engineered to connect an extracellular targeting function with intracellular domains that activate...

Mesenchymal Stromal Cells (MSC´s) in Renal Lupus (MSC-ROLE)


Mesenchymal stem cells (MSCs) are derived from bone marrow and are capable of differentiating into a variety of mesenchymal lineages and also possess...

Voclosporin - VOCAL


Voclosporin is a calcineurin inhibitor which forms a heterodimeric complex with cyclophilin A, which binds to and inhibits calcineurin...

Obinutuzumab - POSTERITY


Obinutuzumab is a humanized, type II anti-CD20 monoclonal antibody that has a distinct mode of binding to the CD20 antigen compared with type I...

Ianalumab - SIRIUS LN


Ianalumab is a fully human monoclonal antibody that targets BAFF-Receptor. It has a novel dual mechanism of action: blockade of BAFF-R-mediated...

Daratumumab


Daratumumab is a monoclonal antibody directed at CD38, which depletes CD38 expressing plasma cells in the bone marrow and a cell-type-specific...

Felzartamab


Felzartamab is a fully human immunoglobulin G1 monoclonal antibody designed to target the highly expressed CD38 cell surface antigen on plasma cells...

YTB323


A chimeric antigen receptor (CAR) is a cellular receptor engineered to connect an extracellular targeting function with intracellular...

List of Updated Clinical Trials for Lupus Nephritis

bottom of page